Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease

Christine Schofield; K. Ray Chaudhuri; Camille Carroll; Jagdish C. Sharma; Nicola Pavese; Jonathan Evans; Thomas Foltynie; Heinz Reichmann; Laura Zurowska; Patrício Soares-Da-Silva; Andrew Lees

doi:10.2217/nmt-2021-0057

Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease

Christine Schofield, K. Ray Chaudhuri, Camille Carroll, Jagdish C. Sharma, Nicola Pavese, Jonathan Evans, Thomas Foltynie, Heinz Reichmann, Laura Zurowska, Patrício Soares-Da-Silva, Andrew Lees^*

^*Corresponding author for this work

Peninsula Medical School

Research output: Contribution to journal › Article › peer-review

11 Downloads (Pure)

Abstract

Aim: This subanalysis of the OPTIPARK study aimed to confirm the effectiveness and safety of opicapone in patients with Parkinson's disease and motor fluctuations in clinical practice specifically in the UK and to assess the impact of opicapone on treatment costs. Methods: Patients received opicapone added to levodopa for 6 months. Clinical outcomes were assessed at 3 and 6 months and treatment costs at 6 months. Results: Most patients' general condition improved at 3 months, with sustained improvements reported at 6 months. Opicapone improved motor and non-motor symptoms at both timepoints, was generally well tolerated and reduced total treatment costs by GBP 3719. Conclusion: Opicapone added to levodopa resulted in clinical improvements and reduced treatment costs across UK clinical practice.

Original language	English
Pages (from-to)	77-91
Number of pages	0
Journal	Neurodegenerative Disease Management
Volume	12
Issue number	2
Early online date	21 Mar 2022
DOIs	https://doi.org/10.2217/nmt-2021-0057
Publication status	Published - Apr 2022

Access to Document

10.2217/nmt-2021-0057

Nmt-2021-0057Licence: CC BY-NC-ND

Cite this

@article{152a687019264464912331c8be55e23c,

title = "Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease",

abstract = " Aim: This subanalysis of the OPTIPARK study aimed to confirm the effectiveness and safety of opicapone in patients with Parkinson's disease and motor fluctuations in clinical practice specifically in the UK and to assess the impact of opicapone on treatment costs. Methods: Patients received opicapone added to levodopa for 6 months. Clinical outcomes were assessed at 3 and 6 months and treatment costs at 6 months. Results: Most patients' general condition improved at 3 months, with sustained improvements reported at 6 months. Opicapone improved motor and non-motor symptoms at both timepoints, was generally well tolerated and reduced total treatment costs by GBP 3719. Conclusion: Opicapone added to levodopa resulted in clinical improvements and reduced treatment costs across UK clinical practice. ",

author = "Christine Schofield and Chaudhuri, {K. Ray} and Camille Carroll and Sharma, {Jagdish C.} and Nicola Pavese and Jonathan Evans and Thomas Foltynie and Heinz Reichmann and Laura Zurowska and Patr{\'i}cio Soares-Da-Silva and Andrew Lees",

year = "2022",

month = apr,

doi = "10.2217/nmt-2021-0057",

language = "English",

volume = "12",

pages = "77--91",

journal = "Neurodegenerative Disease Management",

issn = "1758-2024",

publisher = "Future Medicine Ltd.",

number = "2",

}

TY - JOUR

T1 - Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease

AU - Schofield, Christine

AU - Chaudhuri, K. Ray

AU - Carroll, Camille

AU - Sharma, Jagdish C.

AU - Pavese, Nicola

AU - Evans, Jonathan

AU - Foltynie, Thomas

AU - Reichmann, Heinz

AU - Zurowska, Laura

AU - Soares-Da-Silva, Patrício

AU - Lees, Andrew

PY - 2022/4

Y1 - 2022/4

N2 - Aim: This subanalysis of the OPTIPARK study aimed to confirm the effectiveness and safety of opicapone in patients with Parkinson's disease and motor fluctuations in clinical practice specifically in the UK and to assess the impact of opicapone on treatment costs. Methods: Patients received opicapone added to levodopa for 6 months. Clinical outcomes were assessed at 3 and 6 months and treatment costs at 6 months. Results: Most patients' general condition improved at 3 months, with sustained improvements reported at 6 months. Opicapone improved motor and non-motor symptoms at both timepoints, was generally well tolerated and reduced total treatment costs by GBP 3719. Conclusion: Opicapone added to levodopa resulted in clinical improvements and reduced treatment costs across UK clinical practice.

AB - Aim: This subanalysis of the OPTIPARK study aimed to confirm the effectiveness and safety of opicapone in patients with Parkinson's disease and motor fluctuations in clinical practice specifically in the UK and to assess the impact of opicapone on treatment costs. Methods: Patients received opicapone added to levodopa for 6 months. Clinical outcomes were assessed at 3 and 6 months and treatment costs at 6 months. Results: Most patients' general condition improved at 3 months, with sustained improvements reported at 6 months. Opicapone improved motor and non-motor symptoms at both timepoints, was generally well tolerated and reduced total treatment costs by GBP 3719. Conclusion: Opicapone added to levodopa resulted in clinical improvements and reduced treatment costs across UK clinical practice.

U2 - 10.2217/nmt-2021-0057

DO - 10.2217/nmt-2021-0057

M3 - Article

SN - 1758-2024

VL - 12

SP - 77

EP - 91

JO - Neurodegenerative Disease Management

JF - Neurodegenerative Disease Management

IS - 2

ER -

Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease

Abstract

Access to Document

Fingerprint

Cite this